US Market : Becton Dickinson & Co

Company Description


Becton, Dickinson and Company was incorporated under the laws of the State of New Jersey in November 1906, as successor to a New York business started in 1897. BD is a medical technology company engaged principally in the manufacture and sale of a wide range of medical supplies, devices, laboratory ...



Becton, Dickinson and Company was incorporated under the laws of the State of New Jersey in November 1906, as successor to a New York business started in 1897. BD is a medical technology company engaged principally in the manufacture and sale of a wide range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD's operations consist of three worldwide business segments. BD Medical produces an array of medical devices that are used in a wide range of healthcare settings. They include many safety-engineered injection, infusion and surgery products. The primary markets served by BD Medical are hospitals and clinics; physicians' office practices; consumers and retail pharmacies; public health agencies; pharmaceutical companies; and healthcare workers. BD Diagnostics provides products for the safe collection and transport of diagnostic specimens, and instrumentation for analysis for a range of microbiology and infectious disease testing. BD Diagnostics serves hospitals, laboratories and clinics; reference laboratories; blood banks; healthcare workers; patients; physicians' office practices; and industrial microbiology laboratories. BD Diagnostics' principal products and services are integrated systems for evacuated blood collection; a wide line of safety-engineered specimen collection products and systems; plated media; automated blood culturing; molecular testing systems for sexually transmitted diseases; microorganism identification and drug susceptibility systems; and rapid manual testing products. BD Biosciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. The primary markets served by BD Biosciences are research and clinical laboratories; hospitals and transplant centers; blood banks; and biotechnology and pharmaceutical companies. BD Biosciences' principal product lines include fluorescence activated cell sorters and analyzers; cell imaging systems, monoclonal antibodies and kits; reagent systems for life sciences research; tools to aid in drug discovery and growth of tissue and cells; and diagnostic assays. BD's products are manufactured and sold worldwide. BD's operations outside the United States are conducted in Canada and in five geographic regions: Europe, Japan, Asia Pacific, South Latin America and North Latin America. The principal products sold by BD outside of the United States are hypodermic needles and syringes, insulin syringes and pen needles, diagnostic systems, BD Vacutainer brand blood collection products, BD Hypak brand prefillable syringe systems, infusion therapy products, flow cytometry analyzers and sorters, and disposable laboratory products. BD's products and services are marketed in the U.S. and internationally through independent sales representatives and independent distribution channels, and directly to end-users.

Per Share Data

Earnings (TTM)

4.83



Current P/E ratio

14.51



Cash flow

$6.99



Annual dividend

$1.32



Book value

$21.77



EBIDTA

$2.03B

Profitability

Market cap

$16.75B



Gross margin (TTM)

59.10%



Operating margin (TTM)

29.30%



Profit margin (TTM)

15.70%


This is the best stock i found in Bio-Medical stock. Good profit margin !


Thanks.